Cronos Group Announces New Share Buyback After Strong Quarter
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cronos Group ( (TSE:CRON) ) has provided an announcement.
On May 8, 2026, Cronos extended the long stop date for its planned acquisition of CanAdelaar B.V., one of ten licensed growers in the Dutch Controlled Cannabis Supply Chain Experiment, from June 9 to September 9, 2026, allowing more time for Dutch regulatory clearances, license confirmations and completion of the Bibob background review. On May 11, 2026, the board authorized a new share repurchase program of up to $50 million to run from May 14, 2026 to May 13, 2027, as the company reported record first-quarter 2026 results, including a 40% year-over-year rise in net revenue to $45.2 million, record gross profit, strengthened leadership in Canadian vapes and edibles, nine straight record quarters in Israel, and an industry-leading cash position of about $822 million that underpins its expansion and capital return plans.
The most recent analyst rating on (TSE:CRON) stock is a Buy with a C$4.50 price target. To see the full list of analyst forecasts on Cronos Group stock, see the TSE:CRON Stock Forecast page.
Spark’s Take on CRON Stock
According to Spark, TipRanks’ AI Analyst, CRON is a Neutral.
The score is anchored by strong financial resilience (minimal leverage and substantial liquidity) and improving operating trends (better revenue growth and gross margin). It is held back by still-weak and volatile bottom-line profitability with uneven free cash flow conversion, plus only mixed technical positioning (momentum indicators positive but price below key short/intermediate moving averages). Valuation is also constrained by a negative P/E and no dividend support, while the latest earnings call adds a constructive outlook tempered by near-term execution and margin normalization risks.
To see Spark’s full report on CRON stock, click here.
More about Cronos Group
Cronos Group Inc., listed on Nasdaq and the TSX, operates in the global cannabis industry with a focus on branded adult-use and medical products. The company markets leading brands including Spinach in Canada and PEACE NATURALS in Israel, and is pursuing a “borderless products” strategy to expand its presence across Europe and other international markets.
YTD Price Performance: -3.61%
Average Trading Volume: 157,811
Technical Sentiment Signal: Sell
Current Market Cap: C$1.32B
For detailed information about CRON stock, go to TipRanks’ Stock Analysis page.
